Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective. The company is seeking FDA approval for the treatment; however, the limited data released do not establish efficacy.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s disease. investors.biogen.com http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials (2019).
Biogen. Biogen Q1 2019 Earnings Presentation. investors.bogen.com http://investors.biogen.com/static-files/1e8f9954-58d4-41cf-a6d7-6626338656c3 (2019).
Biogen. Biogen Q3 2019 Earnings Presentation. investors.biogen.com http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c (2019).
Siemers, E. R. et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 12, 110–120 (2016).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
Thompson, B. Statistical significance, result importance, and result generalizability: three noteworthy but somewhat different issues. Meas. Eval. Coun. Dev. 22, 2–6 (1989).
Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. 5, 354–363 (2019).
Strauss D. Biogen surges 42% after stunning reversal sees it revive plans for Alzheimer’s treatment (BIIB). Business Insider https://markets.businessinsider.com/news/stocks/biogen-stock-price-soars-on-plan-to-revive-alzheimers-treatment-2019-10-1028619410 (2019).
The authors declare no competing interests.
About this article
Cite this article
Howard, R., Liu, K.Y. Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol 16, 63–64 (2020). https://doi.org/10.1038/s41582-019-0295-9
Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Biochemical Pharmacology (2020)
Acta Neuropathologica (2020)
An Updated Review of Randomized Clinical Trials Testing the Improvement of Cognitive Function of Ginkgo biloba Extract in Healthy People and Alzheimer’s Patients
Frontiers in Pharmacology (2020)
Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E
Molecular Neurodegeneration (2020)
Scientific Reports (2020)